Preclinical development of anti-BCMA immunotoxins targeting multiple myeloma.

Shancer, Zoe; Williams, Matthew; Igelman, Austin; Nagata, Satoshi; Ise, Tomoko; Pastan, Ira; Bera, Tapan K

Shancer, Zoe; Williams, Matthew; Igelman, Austin; Nagata, Satoshi; Ise, Tomoko; Pastan, Ira; Bera, Tapan K.

Afiliación

Shancer Z; Laboratory of Molecular Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892,USA.
Williams M; Laboratory of Molecular Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892,USA.
Igelman A; Laboratory of Molecular Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892,USA.
Nagata S; National Institutes of Biomedical Innovation, Health and Nutrition, Osaka 5670085, Japan.
Ise T; National Institutes of Biomedical Innovation, Health and Nutrition, Osaka 5670085, Japan.
Pastan I; Laboratory of Molecular Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892,USA.
Bera TK; Laboratory of Molecular Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892,USA.

Antib Ther ; 1(1): 19-25, 2018 Jun.

Article en En | MEDLINE | ID: mdl-30272049

Palabras clave

ABD fusion protein; LMB-75; mAb BM306; mAb C11D5.3; mAb J22.9

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Antib Ther Año: 2018 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google